NYMC > Center for Disaster Medicine > The COVID‐19 Vaccine: What to Tell Your Patients

The COVID‐19 Vaccine: What to Tell Your Patients

Link to Webinar and material for claiming CME credit. www.eeds.com/em/2043


Speaker Biographies

  1. Robert Amler, M.D., M.B.A., is Vice President for Government Affairs here at New York Medical College. He is also Dean of the School of Health Sciences and Practice and Institute of Public Health, and Professor of Public Health, Pediatrics, and Environmental Health Science. He has expanded the school in many directions and co-founded the newly expanded biotech incubator, BioInc, funded in part by New York State, to attract and support researchers and start-ups in early-stage development of new drugs, vaccine strains, medical devices and medical apps. His latest project is the new Touro dental school and clinic on this campus, which received New York State funding in the most recent cycle. Before joining NYMC, Dr. Amler was Regional Health Administrator for the federal government in the Northeast and Caribbean region, with a population of 32 million, and secured major supplemental Medicaid funding for New York, New Jersey and Puerto Rico. Still a practicing physician, Dr. Amler is a former Chief Medical Officer and Epidemic Intelligence Service Officer of the Centers for Disease Control.

  2. Kathleen DiCaprio, Ph.D., is an assistant professor of medical microbiology and immunology at the Touro College of Osteopathic Medicine. She earned her Ph.D. in pathology from Uniformed Services University of the Health Sciences and is a Kaplan USMLE Step 1 instructor for immunology and microbiology. Previously she worked for the New York City DOHMH Public Health Laboratory where she assisted in laboratory and emergency responses during the H1N1 Influenza outbreak in 2009. Dr. DiCaprio’s prior research included exploring pathogenic mechanisms as well as vaccine development for BSL-4 viral hemorrhagic fever viruses, including Ebola and Marburg, as well as Nipah and Lassa viruses. Dr. DiCaprio was part of a research team at The United States Army Research Institute of Infectious Diseases (USAMRIID) that developed and studied the VSV-Ebola vaccine, which served foundational to the advancement and FDA approval for human use several years later. Dr. DiCaprio has also served as a consultant in areas of laboratory biosafety, emergency responses and animal laboratory sciences for Boston University’s National Emerging Infectious Disease Laboratories.  

Series Objectives:

  1. Educate providers on how to best inform patients on the current science and risks/benefits of the COVID‐19 vaccine.
  2. Discuss strategies on how to approach vaccine avoidance in patients.

Accreditation Statement:

New York Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

  • The New York Medical College designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The New York Medical College designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Event Disclosures:


  • Robert Amler, M.D., M.B.A., and Kathleen DiCaprio, Ph.D. report having no actual or potential conflict of interest in relation to this educational activity.

Planners and other Administrative Support:

  • Kevin Pohlman, M.Ed. has no relevant financial relationships to report in the last 12 months with a commercial interest.

Commercial Support:

This activity is not commercially supported.

Other Comments:

Release and Expiration
Date of original release: January 25, 2021
Date of Expiration: January 25, 2024
This activity is designed to be completed within 30 minutes. To successfully earn credit, participants must complete the online post‐test and evaluation. You must receive a minimum of 70% on the post‐te